The First Pavlov State Medical University of St. Petersburg is a higher education institution, medical university in St. Petersburg. PSPbGMU is called the First Medical Institute in St. Petersburg because of its renaming in 1936, relative to Saint Petersburg State Medical Academy named after I.I.

During the past decade, Pavlov First Saint Petersburg State Medical University conducted 119 clinical trials. In the 10-year time frame, 119 clinical trials started and 61 clinical trials were completed, i.e. on average, 51.3% percent of trials that started reached the finish line to date. In the past 5 years, 36 clinical trials started and 31 clinical trials were completed. i.e. 86.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Pavlov First Saint Petersburg State Medical University" #1 sponsor was "Hoffmann-La Roche" with 22 trials, followed by "St. Petersburg State Pavlov Medical University" with 22 trials sponsored, "Celgene" with 13 trials sponsored, "Pfizer" with 9 trials sponsored and "Eli Lilly and Company" with 9 trials sponsored. Other sponsors include 125 different institutions and companies that sponsored additional 87 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Pavlov First Saint Petersburg State Medical University" #1 collaborator was "National Institute on Drug Abuse (NIDA)" with 5 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 4 trials as a collaborator, "St. Petersburg State Pavlov Medical University" with 4 trials as a collaborator, "National Institute on Alcohol Abuse and Alcoholism (NIAAA)" with 3 trials as a collaborator and "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator. Other collaborators include 53 different institutions and companies that were collaborators in the rest 60 trials.

According to Clinical.Site data, the most researched conditions in "Pavlov First Saint Petersburg State Medical University" are "Ulcerative Colitis" (13 trials), "Myelodysplastic Syndromes" (7 trials), "Multiple Sclerosis" (6 trials), "Non-Hodgkin's Lymphoma" (6 trials) and "Carcinoma, Non-Small-Cell Lung" (5 trials). Many other conditions were trialed in "Pavlov First Saint Petersburg State Medical University" in a lesser frequency.

Most popular intervention types in "Pavlov First Saint Petersburg State Medical University" are "Drug" (176 trials), "Biological" (19 trials), "Other" (16 trials), "Procedure" (15 trials) and "Behavioral" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (49 trials), "Rituximab" (8 trials), "Cyclophosphamide" (7 trials), "Docetaxel" (7 trials) and "Carboplatin" (6 trials). Other intervention names were less common.

The vast majority of trials in "Pavlov First Saint Petersburg State Medical University" are 192 trials for "All" genders, 6 trials for "Male" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Pavlov First Saint Petersburg State Medical University". undefined are not yet recruiting, 36 are recruiting, 26 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 110 completed trials in Pavlov First Saint Petersburg State Medical University, undefined suspended trials, and 24 terminated clinical trials to date.

Out of the total trials that were conducted in Pavlov First Saint Petersburg State Medical University, 22 "Phase 1" clinical trials were conducted, 55 "Phase 2" clinical trials and 115 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 13 trials that are defined as “Not Applicable".